ADC Therapeutics is a leveraged, single-product biotech option where ZYNLONTA’s second-line regulatory fate could either unlock major upside or threaten the company’s commercial foundation.
Overview
ADC Therapeutics is a commercial-stage oncology biotech built around ZYNLONTA, an FDA-approved CD19-targeting antibody-drug conjugate for relapsed/refractory DLBCL. Its value proposition is accessibility: ZYNLONTA is an off-the-shelf outpatient therapy that avoids the logistical burden and toxicities of CAR-T. Revenue comes from U.S. product sales plus international licensing, milestones, and royalties through partners such as Sobi, MTPC, and Overland. The investment case is high-risk and highly concentrated, with meaningful upside from label expansion but major dependence on one drug, regulatory outcomes, and balance-sheet durability.